Explore the words cloud of the SAFER project. It provides you a very rough idea of what is the project "SAFER" about.
The following table provides information about the project.
|Coordinator Country||Denmark [DK]|
|Total cost||1˙286˙630 €|
|EC max contribution||1˙286˙630 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2017-09-01 to 2021-08-31|
Take a look of project's partnership.
|1||KOBENHAVNS UNIVERSITET||DK (KOBENHAVN)||coordinator||290˙081.00|
|2||SAROMICS BIOSTRUCTURES AB||SE (Lund)||participant||512˙670.00|
|3||ENAMINE LIMITED LIABILITY COMPANY,RESEARCH AND PRODUCTION ENTERPRISE||UA (KYIV)||participant||483˙878.00|
SAFER will train 5 ESRs, PhD students, to obtain ample scientific, business and transferrable skills, arming them with the expertise to translate knowledge into products and services with importance for European industry and society. All ESRs will first train together at one university to develop complementary skills and basic research data; and subsequently move to two SMEs for applied and commercial research.
The ultimate scientific goal for the SAFER program is to gain molecular understanding and improve selectivity in treatments of CNS-related disorders. This will be done through an interdisciplinary and intersectoral approach, building on a strong complementarity between partners, with a particular focus on the serotonin 5-HT2A receptor – the primary target for many pharmaceuticals and hallucinogens. SAFER will generate and cross-interpret pharmacology and crystallographic data, and construct computational mechanistic models and databases that can explain and guide its experiments. Thus, SAFER will gain new insights into molecular mechanisms that are fundamental to understand the biological and therapeutic effects, and to develop safer drugs. SAFER ESRs will be highly competitive on the job market and much in demand. In particular, crystallography and biased signalling pharmacology of G protein-coupled receptors (e.g. 5-HT2A) are new and highly active research fields, today mastered by only a very few research groups worldwide. The timing and location of SAFER are particularly opportune, taking advantage of the new synchrotron MAX IV in Lund, Sweden, which is world leading for the study of challenging crystals. SAFER will seek to exploit innovation opportunities from novel molecular mechanisms, ligands, and crystal structures. The results will be integrated into a public community resource, GPCRdb, giving a unique potential to achieve community impact and long-term sustainability.
|2nd report on dissemination activities||Documents, reports||2019-10-03 18:10:31|
|SAFER web site||Websites, patent fillings, videos etc.||2019-07-24 18:15:34|
|1st report on dissemination activities||Documents, reports||2019-07-24 18:15:34|
Take a look to the deliverables list in detail: detailed list of SAFER deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAFER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SAFER" are provided by the European Opendata Portal: CORDIS opendata.
Training school on entrainment in offshore wind powerRead More
BestTreat – Building a Gut Microbiome Engineering Toolbox for In-Situ Therapeutic Treatments for Non-alcoholic Fatty Liver DiseaseRead More
European School of Network NeuroscienceRead More